NanoVibronix Reports Successful Trial Results for Use of PainShield(TM) in Patients with Trigeminal Neuralgia; Reinforces Potential as Alternative to Opioids and Surgical Interventions

Stock Information for NanoVibronix Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About NanoVibronix Inc.

NanoVibronix Issues Letter to Stockholders
NanoVibronix Signs Agreement for Research and Development of Next Generation PainShield and UroShield
NanoVibronix Featured in Your Bladder Health Magazine
NanoVibronix Enters into Letter of Intent with APOGEPHA Arzneimittel GmbH to Explore European Distribution Opportunity
NanoVibronix Announces Agreement for Clinical Study of UroShield at the University of Michigan
NanoVibronix Regains Nasdaq Compliance
NanoVibronix Issues Letter to Shareholders
NanoVibronix UroShield Products Available on NHS Drug Tariff Effective November 1

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.